Please be advised: Linagliptin is an investigational compound and not approved for clinical use. Please be aware that there may be national differences between countries regarding specific medical information, including licenced uses. Please take into account the information here is designed to supply you with current news in pharmaceutical and medical research and not to promote clinical use of the substances mentioned on this site.
Dr. Julio Rosenstock, MD, USA - Biography

Watch on iPhone/iPad
Dr. Jonathan Brown, MPP, PhD, International Diabetes Federation - Biography

Watch on iPhone/iPad
Dr. Steven E. Kahn, MB ChB, USA - Biography

Watch on iPhone/iPad
Dr. Bernard Zinman, MD, Canada - Biography

Watch on iPhone/iPad
Dr. Hans-Juergen Woerle, MD, Boehringer Ingelheim

Watch on iPhone/iPad
Contact

Ursula Bardon

Corporate Communications
Boehringer Ingelheim GmbH
55216 Ingelheim / Germany

Phone: +49-6132-77 2622
Fax: +49-6132-72 2622
E-mail: press@boehringer-ingelheim.com

Download Section
Press Release
• Boehringer Ingelheim announces results of linagliptin phase III data...
Agenda
• Agenda
Fact Sheets
• Type 2 diabetes
• Linagliptin in type 2 diabetes
• Renal diseases in type 2 diabetes
Visuals
• Diabetes Complications
• Boehringer Ingelheim's Commitment
  to R&D in Diabetes
Videos
Mode of Action of DPP-4 Inhibitors
(Watch on iPhone/iPad)

Diabetes Complications Animation
(Watch on iPhone/iPad)

Diabetes Health Lounge
bottom
Terms of use    Imprint